Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM1022 in advanced tumors
ChiCTR2200060451Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PM1022 in Non-hematologic malignancy, sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicity within 21 days after first administration and Objective response rate in Phase IIa. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
PM1022
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2200060451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060451.